NCT03292263View on ClinicalTrials.gov

ASCT With Nivolumab in Patients With Multiple Myeloma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Melphalan

iv infusion 70-100 mg/m2 on day -3, -2

DRUG

Nivolumab

iv infusion 100 mg on day -3, +17

PROCEDURE

Autologous Stem Cell Transplantation

peripheral blood stem cell transfusion at day 0

Trial Locations (1)

197089

Boris V Afanasyev, MD, Prof., Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER